COMMUNIQUÉS West-GlobeNewswire

BioCardia Reports First Quarter 2025 Business Highlights and Financial Results
14/05/2025
SUNNYVALE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported [...]
Codexis Reports First Quarter 2025 Financial Results
14/05/2025
Secured first revenue-generating contract for ECO Synthesis™ manufacturing services Company reiterates full-year financial guidance Six presentations to feature the ECO Synthesis platform at upcoming TIDES USA annual [...]
Tenax Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
14/05/2025
Phase 3 LEVEL Enrollment Completion for TNX-103 in PH-HFpEF Targeted Around Year-End 2025, with Topline Data Expected Middle of 2026 Initiation of Second Phase 3 Study, LEVEL-2, Expected This Year CHAPEL HILL, N.C., May [...]
STRATA Skin Sciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update
14/05/2025
HORSHAM, Pa., May 14, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative [...]
Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress
14/05/2025
First patient dosed in DENALI Part 2a clinical trial of azenosertib in patients with Cyclin E1+ PROC Topline data from DENALI Part 2 anticipated by year end 2026 with the potential to support an accelerated approval, [...]
Jade Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Update
14/05/2025
Completed reverse merger and commenced trading on Nasdaq as JBIO Closed financing, raising approximately $300 million to date, providing cash runway through 2027 Lead candidate JADE101 expected to enter the clinic in [...]
ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2025
14/05/2025
PORTLAND, Maine, May 14, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and [...]
AEON Biopharma Reports First Quarter 2025 Financial Results and Provides Corporate Update
14/05/2025
– Continue to conduct analytical studies to prepare for a potential Biosimilar Biological Product Development (“BPD”) Type 2a meeting with the FDA in the second half of 2025 – – Pursuing a 351(k) regulatory pathway for [...]
Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity
14/05/2025
Advancing IKT-001 into a Late-Stage Clinical Trial Program in Pulmonary Arterial Hypertension BOSTON and ATLANTA, May 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company [...]
Silo Pharma Selects Veloxity Labs for Bioanalytical IND-Enabling Study for our Novel Intranasal PTSD Therapy, SPC-15
14/05/2025
SARASOTA, FL, May 14, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today [...]
Aardvark Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights
14/05/2025
Phase 3 HERO trial of ARD-101 for the treatment of hyperphagia associated with Prader-Willi Syndrome (PWS); data readout expected in early 2026 $151.3 million in cash, cash equivalents, and short-term investments [...]
GENFIT : Publication du rapport de performance extra-financière 2025 (exercice 2024)
14/05/2025
Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 14 mai 2025 – GENFIT (Nasdaq et Euronext : GNFT) , société biopharmaceutique engagée dans l’amélioration de la vie des patients atteints de [...]
GENFIT: Publication of the 2025 Extra-Financial Performance Report (fiscal year 2024)
14/05/2025
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 14, 2025- GENFIT (Nasdaq and Euronext: GNFT) , a biopharmaceutical company dedicated to improving the lives of patients with rare and [...]
X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress
14/05/2025
Meaningful and durable increases in functional neutrophils observed over 6-month trial with oral once-daily mavorixafor Majority of physicians and chronic neutropenia participants chose to significantly reduce G-CSF [...]
Oruka Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
14/05/2025
Continued operational excellence leading to acceleration of multiple timelines: ORKA-001, targeting IL-23p19, Phase 1 trial dosing complete, with data expected in 3Q 2025 ORKA-001 Phase 2a initiation expected in 2H 2025 [...]
Edesa Biotech Reports Fiscal 2nd Quarter 2025 Results
14/05/2025
TORONTO, May 14, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported [...]
FibroBiologics Reports First Quarter 2025 Financial Results and Provides Corporate Update
14/05/2025
Preparations for Phase 1/2 clinical trial in Australia utilizing fibroblast-based spheroids product candidate, CYWC628, to treat diabetic foot ulcers are proceeding with plans to initiate in the third quarter of 2025 [...]
Catheter Precision, Inc. Announces First Quarter 2025 Update and Financial Results
14/05/2025
FORT MILL, S.C., May 14, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced its financial [...]
Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights
14/05/2025
Bolstered management team with hires of Chief Executive Officer and Chief Medical Officer with deep biopharmaceutical experience Announced selection of IL15-superagonist as first payload to be delivered into tumors with [...]

Pages